LACTIN-V

Phase 2Small molecule

UUniversity of California, San Francisco

LACTIN-V is one of 52 small molecule programs targeting Bacterial Vaginosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial VaginosisActive, not recruiting

Urinary Tract InfectionActive, not recruiting

Bacterial VaginosisPhase 2

Active, not recruiting

Urinary Tract InfectionPhase 2

Active, not recruiting

Competition

Competitive Landscape

163 competitors in Urinary Tract Infection

#DrugCompanyPhaseTrials

Maxipime

Pfizer

Phase 3

3 2

Medrol

Pfizer

Phase 3

1 3

Merrem

BB. Braun Medical Inc.

Phase 3

7 4

Rocephin

CConrado Roberto Hoffmann Filho

Phase 3

2 5

Decadron

AAspen Global Incorporated

Phase 3

1 6

Piperacillin/tazobactam

Pfizer

Phase 3

1 7

Prulifloxacin

Merck & Co.

Phase 3

1 8

Amoxicillin/clavulanate Potassium

Johnson & Johnson

Phase 3

1 9

Blujepa

GGlaxo Dba Glaxosmithkline

Phase 3

5 10

Amoxicillin/clavulanate

Bayer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

High Risk1 trial

Phase 2 Trial of LACTIN-V in Women at High Risk of HIV Acquisition

Completed·UUniversity of California, San Francisco·Phase 2·NCT05022212·45 enrolled

Urinary Tract Infection1 trial

Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection

Completed·UUniversity of Washington·Phase 2·NCT00305227·100 enrolled

Bacterial Vaginosis1 trial

Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis

Completed·OOsel, Inc.·Phase 2·NCT00635622·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for LACTIN-V. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LACTIN-V compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LACTIN-V. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Francisco company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of California, San Francisco

LACTIN-V

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

High Risk1 trial

Urinary Tract Infection1 trial

Bacterial Vaginosis1 trial

References

Drug Info

Quick Facts

Related News